Targeted thrombolysis by using c-RGD-modified N,N,N-Trimethyl Chitosan nanoparticles loaded with lumbrokinase

References

• Krishnamurthi RV, Moran AE, Feigin VL, et al. Stroke prevalence, mortality and disability-adjusted life years in adults aged 20–64 years in 1990–2013: data from the global burden of disease 2013 study. Neuroepidemiology. 2015;45:190–202.
   PubMed Web of Science ®Google Scholar
• Grove EL, Lankeit M, Hess K, et al. CardioPulse Articles Big heart disease: new insights from studies of a million people. The ‘Young Thrombosis Researchers Group’of the ESC Working Group on Thrombosis. The burden of Cardiovascular Disease in India. The atrial septal defect: do we know everything? Drinking tea reduces non-cardiovascular mortality by 24% People’s corner: Professor Thomas Münzel MD award. Eur Heart J. 2015;36:702–707.
   PubMedGoogle Scholar
• Siddiqui T, S AK, Dikshit D. Platelets and atherothrombosis: causes, targets and treatments for thrombosis. Cmc. 2013;20:2779–2797.
   PubMed Web of Science ®Google Scholar
• Absar S, Nahar K, Kwon YM, et al. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy. Pharm Res. 2013;30:1663–1676.
   PubMed Web of Science ®Google Scholar
• Mattila OS, Sairanen T, Laakso E, et al. Cerebral amyloid angiopathy related hemorrhage after stroke thrombolysis: case report and literature review. Neuropathology. 2015;35:70–74.
   PubMed Web of Science ®Google Scholar
• Wardlaw JM, Koumellis P, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Lib. 2013;5:CD000514.
   Google Scholar
• Jin H, Tan H, Zhao L, et al. Ultrasound-triggered thrombolysis using urokinase-loaded nanogels. Int J Pharm. 2012;434:384–390.
   PubMed Web of Science ®Google Scholar
• Kim J-Y, Kim J-K, Park J-S, et al. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials. 2009;30:5751–5756.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang J, Yuan Z, et al. Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles. J Biomed Nanotechnol. 2012;8:624–632.
   PubMed Web of Science ®Google Scholar
• Wang F, Wang C, Li M, et al. Purification, characterization and crystallization of a group of earthworm fibrinolytic enzymes from Eisenia fetida. Biotechnol Lett. 2003;25:1105–1109.
   PubMed Web of Science ®Google Scholar
• Lee CK, Shin JS, Kim BS, et al. Antithrombotic effects by oral administration of novel proteinase fraction from earthworm Eisenia andrei on venous thrombosis model in rats. Arch Pharm Res. 2007;30:475–480.
   PubMed Web of Science ®Google Scholar
• Yan XM, Kim C-H, Lee CK, et al. Intestinal absorption of fibrinolytic and proteolytic lumbrokinase extracted from earthworm, Eisenia andrei. Korean J Physiol Pharmacol. 2010;14:71–75.
   PubMed Web of Science ®Google Scholar
• Zhou J, Guo D, Zhang Y, et al. Construction and evaluation of Fe3O4-based PLGA nanoparticles carrying rtPA used in the detection of thrombosis and in targeted thrombolysis. ACS Appl Mater Interfaces. 2014;6:5566–5576.
   PubMed Web of Science ®Google Scholar
• Jin M, Chen W, Huang W, et al. Preparation of pegylated lumbrokinase and an evaluation of its thrombolytic activity both in vitro and in vivo. Acta Pharmaceutica Sinica B. 2013;3:123–129.
   Google Scholar
• Chua BY, Al Kobaisi M, Zeng W, et al. Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines. Mol Pharmaceutics. 2012;9:81–90.
   PubMed Web of Science ®Google Scholar
• Amidi M, Mastrobattista E, Jiskoot W, et al. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev. 2010;62:59–82.
   PubMed Web of Science ®Google Scholar
• Bernkop-Schnürch A, Dünnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm. 2012;81:463–469.
   PubMed Web of Science ®Google Scholar
• Kampf N, Raviv U, Klein J. Normal and shear forces between adsorbed and gelled layers of chitosan, a naturally occurring cationic polyelectrolyte. Macromolecules. 2004;37:1134–1142.
   Web of Science ®Google Scholar
• Qi L, Xu Z, Jiang X, et al. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res. 2004;339:2693–2700.
   PubMed Web of Science ®Google Scholar
• Kotzé AF, Luessen HL, de Leeuw BJ, et al. Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J Control Rel. 1998;51:35–46.
   PubMed Web of Science ®Google Scholar
• Mao S, Germershaus O, Fischer D, et al. Uptake and transport of PEG-graft-trimethyl-chitosan copolymer–insulin nanocomplexes by epithelial cells. Pharm Res. 2005;22:2058–2068.
   PubMed Web of Science ®Google Scholar
• Sadeghi A, Dorkoosh F, Avadi M, et al. Preparation, characterization and antibacterial activities of chitosan, N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation methods. Int J Pharm. 2008;355:299–306.
   PubMed Web of Science ®Google Scholar
• Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology. Nanomedicine. 2013;8:773–784.
   PubMed Web of Science ®Google Scholar
• Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. The Lancet. 2002;359:189–198.
   PubMed Web of Science ®Google Scholar
• Boersma E, Akkerhuis KM, Théroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045–2048.
   PubMed Web of Science ®Google Scholar
• Srinivasan R, Marchant RE, Gupta AS. In vitro and in vivo platelet targeting by cyclic RGD‐modified liposomes. J Biomed Mater Res. 2009;9999A:NA–1015.
   Google Scholar
• Huang G, Gupta AS, Kottke-Marchant K, et al.,. editors. Targeting Efficiency Optimization of RGD-Modified Liposomes to Activated Platelets. Annual meeting-society for biomaterials in conjunction with the international biomaterials symposium; 2006.
   Google Scholar
• Huang G, Zhou Z, Srinivasan R, et al. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. Biomaterials. 2008;29:1676–1685.
   PubMed Web of Science ®Google Scholar
• Hua X, Zhou L, Liu P, et al. In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model. J Thromb Thrombolysis. 2014;38:57–64.
   PubMed Web of Science ®Google Scholar
• Laing ST, Moody MR, Kim H, et al. Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model. Thrombosis Res. 2012;130:629–635.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhou J, Guo D, et al. Preparation and characterization of gadolinium-loaded PLGA particles surface modified with RGDS for the detection of thrombus. Int J Nanomed. 2013;8:3745.
   PubMed Web of Science ®Google Scholar
• Wang S, Jiang T, Ma M, et al. Preparation and evaluation of anti-neuroexcitation peptide (ANEP) loaded N-trimethyl chitosan chloride nanoparticles for brain-targeting. Int J Pharm. 2010;386:249–255.
   PubMed Web of Science ®Google Scholar
• Sieval A, Thanou M, Kotze A, et al. Preparation and NMR characterization of highly substitutedN-trimethyl chitosan chloride. Carbohydrate Pol. 1998;36:157–165.
   Web of Science ®Google Scholar
• Chen F, Zhang Z-R, Yuan F, et al. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int J Pharm. 2008;349:226–233.
   PubMed Web of Science ®Google Scholar
• Lu Y-m, Huang J-y, Wang H, et al. Targeted therapy of brain ischaemia using Fas ligand antibody conjugated PEG-lipid nanoparticles. Biomaterials. 2014;35:530–537.
   PubMed Web of Science ®Google Scholar
• Jeong YK, Park JU, Baek H, et al. Purification and biochemical characterization of a fibrinolytic enzyme from Bacillus subtilis BK-17. World J Microbiol Biotechnol. 2001;17:89–92.
   Web of Science ®Google Scholar
• DONG Z-k, YANG C, YIN Z-n, et al. Study on purification and enzyme kinetics of nattokinase. Chin J Biochem Pharm. 2009;5:004.
   Google Scholar
• Yang H-W, Hua M-Y, Lin K-J, et al. Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis. Int J Nanomed. 2012;7:5159.
   PubMed Web of Science ®Google Scholar
• Tadayon A, Jamshidi R, Esmaeili A. Delivery of tissue plasminogen activator and streptokinase magnetic nanoparticles to target vascular diseases. Int J Pharm. 2015;495:428–438.
   PubMedGoogle Scholar
• Kurz K, Main B, Sandusky G. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 1990;60:269–280.
   PubMed Web of Science ®Google Scholar
• Jin H-j, Zhang H, Sun M-l, et al. Urokinase-coated chitosan nanoparticles for thrombolytic therapy: preparation and pharmacodynamics in vivo. J Thromb Thrombolysis. 2013;36:458–468.
   PubMed Web of Science ®Google Scholar